Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02942004
Other study ID # 547-PPD-202 B
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 1, 2016
Est. completion date October 19, 2017

Study information

Verified date January 2022
Source Sage Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo injection as assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total score.


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date October 19, 2017
Est. primary completion date September 24, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Key Inclusion Criteria: - Participants must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s) from just prior to receiving study drug through nine days (Day 12) after the end of the infusion - Participants had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) - Participant had a HAM-D total score of =26 at screening and Day 1 (prior to dosing) - Participant was =6 months postpartum at screening - Participant was amenable to IV therapy Key Exclusion Criteria: - Active psychosis - Attempted suicide associated with index case of postpartum depression - Medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder. Note: Other protocol-defined inclusion/exclusion criteria applied.

Study Design


Intervention

Drug:
Placebo
Intravenous infusion of matching placebo for either SAGE-547 60 µg/kg/h or 90 µg/kg/h.
SAGE-547 60 µg/kg/h
Intravenous infusion of SAGE-547.
SAGE-547 90 µg/kg/h
Intravenous infusion of SAGE-547.

Locations

Country Name City State
United States Sage Investigational Site Atlanta Georgia
United States Sage Investigational Site Boston Massachusetts
United States Sage Investigational Site Boston Massachusetts
United States Sage Investigational Site Chandler Arizona
United States Sage Investigational Site Chapel Hill North Carolina
United States Sage Investigational Site Charlotte North Carolina
United States Sage Investigational Site Columbus Ohio
United States Sage Investigational Site Dayton Ohio
United States Sage Investigational Site Edgewood Kentucky
United States Sage Investigational Site Flowood Mississippi
United States Sage Investigational Site Gainesville Florida
United States Sage Investigational Site Glen Oaks New York
United States Sage Investigational Site Hoffman Estates Illinois
United States Sage Investigational Site Houston Texas
United States Sage Investigational Site Houston Texas
United States Sage Investigational Site Lemon Grove California
United States Sage Investigational Site Marlton New Jersey
United States Sage Investigational Site Miami Florida
United States Sage Investigational Site Miramar Florida
United States Sage Investigational Site Orange California
United States Sage Investigational Site Orem Utah
United States Sage Investigational Site Orlando Florida
United States Sage Investigational Site Owensboro Kentucky
United States Sage Investigational Site Pensacola Florida
United States Sage Investigational Site Philadelphia Pennsylvania
United States Sage Investigational Site Pinellas Park Florida
United States Sage Investigational Site Raleigh North Carolina
United States Sage Investigational Site Richardson Texas
United States Sage Investigational Site Rogers Arkansas
United States Sage Investigational Site San Antonio Texas
United States Sage Investigational Site Ventura California
United States Sage Investigational Site Wichita Kansas

Sponsors (1)

Lead Sponsor Collaborator
Sage Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, Hour 60
Secondary Change From Baseline in HAM-D Total Score at Day 30 The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, Day 30
Secondary Change From Baseline in HAM-D Total Score The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14, and 21
Secondary Percentage of Participants With HAM-D Response The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Hour 60, Days 7 and 30
Secondary Percentage of Participants With HAM-D Remission The HAM-D remission is defined as having a HAM-D total score of =7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Hour 60, Days 7 and 30
Secondary Change From Baseline in HAM-D Bech 6 Subscale The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, Hour 60, Days 7 and 30
Secondary Change From Baseline in HAM-D Individual Item Scores The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, Hour 2, Hour 4, Hour 8, Hour 12, Hour 24, Hour 36, Hour 48, Hour 60, Hour 72 and Days 7, 14, 21 and 30
Secondary Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression. Baseline, Hour 60, Days 7 and 30
Secondary Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions. CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). Hour 60, Days 7 and 30
Secondary Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety. Baseline, Hour 60, Days 7, 14, 21 and 30
Secondary Percentage of Participants With Treatment-Emergent Adverse Events An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent AE (TEAE) is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion. Up to approximately 37 days.
Secondary Time to Change in Antidepressant Medication The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication. Up to approximately 37 days.
See also
  Status Clinical Trial Phase
Recruiting NCT06348316 - Early Half Swaddling and Kangaroo Care Practices on Maternal Sleep Quality and Postpartum Depression in Term Babies N/A
Completed NCT05322161 - Yoga in the NICU for Parents Study N/A
Withdrawn NCT03709004 - Pacifiers and Breastfeeding Among Mothers at Risk for Postpartum Depression N/A
Completed NCT06305325 - Coparenting Intervention to Prevent Postpartum Depression N/A
Not yet recruiting NCT05055674 - The Effects of Motherly on Postpartum Depression N/A
Enrolling by invitation NCT02323152 - PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK N/A
Not yet recruiting NCT01658098 - Prevalence of Postpartum Depression in Hospital Jose E. Gonzalez N/A
Completed NCT00961402 - The Effect of Exercise on Preventing PostPartum Depression Phase 2
Completed NCT01312883 - Mothers Avoiding Depression Through Empowerment Intervention Trial N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Unknown status NCT00548743 - Translating Research Into Practice for Postpartum Depression N/A
Completed NCT04146025 - Nurtured in Nature N/A
Not yet recruiting NCT06442774 - MamaConecta: Digital Tool for Maternal Mental Health N/A
Recruiting NCT05137925 - Mindful Moms: Mechanisms of Mindfulness-based Cognitive Therapy During Pregnancy and Postpartum N/A
Not yet recruiting NCT05299398 - Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone Phase 1
Completed NCT04925765 - Virtual Reality Biofeedback for Postpartum Anxiety and Depression N/A
Recruiting NCT06053515 - Rosie the Chatbot: Leveraging Automated and Personalized Health Information Communication N/A
Completed NCT04037085 - Ketamine to Improve Recovery After Cesarean Delivery - Part 1 Phase 2
Completed NCT05059600 - A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting Phase 4
Completed NCT06136520 - The Effect of Baby Massage Training Given to Pregnant Women on Maternal Attachment and Postpartum Depression N/A

External Links